Dosing Guide
Mounjaro Dose Schedule Guide: Understanding Every Dose Step
Quick Answer: Mounjaro treatment begins at 2.5 mg once weekly and increases every four weeks through 5 mg, 7.5 mg, 10 mg and 12.5 mg before reaching the maximum maintenance dose of 15 mg at approximately week 21. The gradual escalation is designed to reduce side effects and allow the body to adapt to tirzepatide's dual GLP-1/GIP mechanism. Not all patients need to reach 15 mg — some maintain excellent results at 10 mg or 12.5 mg. All doses are administered as a once-weekly subcutaneous injection.6 stepsin the Mounjaro dose escalation schedule
20 weeksto reach 15 mg maintenance dose
15 mgmaximum licensed maintenance dose
Why Doses Increase Gradually
Why Mounjaro Doses Increase Gradually
Mounjaro does not begin at its full therapeutic dose. Instead, patients follow a six-step escalation schedule spanning approximately 20 weeks before reaching the 15 mg maximum dose. This approach is a core feature of tirzepatide's clinical design — not simply a formality — and is directly responsible for the treatment's tolerability profile.
Reducing Gastrointestinal Side Effects
Tirzepatide's dual action on GLP-1 and GIP receptors throughout the gastrointestinal tract produces meaningful changes in gastric motility from the first injection. Starting at 2.5 mg — a dose insufficient for full therapeutic appetite suppression — introduces these receptor changes gradually, allowing the gut to adapt before the next dose increase. Without this structured approach, the full GI impact of tirzepatide at therapeutic concentrations would be experienced immediately, producing severely elevated rates of nausea, vomiting and diarrhoea that would make the treatment practically intolerable for most patients.
Receptor Adaptation
GLP-1 and GIP receptors in the gut and brain partially down-regulate their sensitivity in response to sustained agonism — a process of biological adaptation that reduces the intensity of side effects over time. The four-week intervals between Mounjaro dose increases are timed to allow this receptor adaptation to occur at each level before stimulation is increased further. This is why patients who skip steps or escalate ahead of schedule reliably experience a resurgence of side effects: their receptors have not had adequate time to adapt to the current dose before the next level of stimulation is introduced.
Optimising Long-Term Outcomes
Completing the full escalation schedule and reaching the highest tolerated dose — ideally 15 mg — produces the greatest clinical outcomes. SURMOUNT-1 data shows that patients at 15 mg achieved average weight loss of 22.5% at 72 weeks, compared with 19.5% at 10 mg. The escalation schedule is therefore an investment in results, not merely a safety precaution. Patients who rush escalation and discontinue due to side effects lose both the tolerability benefit and the efficacy opportunity that the schedule is designed to deliver.
Full Schedule
Mounjaro Dose Escalation Chart
The table below provides the complete Mounjaro dosing schedule from first injection to maintenance, reflecting the MHRA-approved Summary of Product Characteristics and NICE TA1026.
| Dose | Timeline | Purpose | Side Effects | Key Advice | Status |
|---|---|---|---|---|---|
| 2.5 mg | Weeks 1–4 | Tolerability dose | Mild nausea possible | Do not increase early | Escalation |
| 5 mg | Weeks 5–8 | First escalation | Nausea may increase | Monitor GI tolerance | Escalation |
| 7.5 mg | Weeks 9–12 | Second escalation | Peak nausea period | Eat smaller meals | Escalation |
| 10 mg | Weeks 13–16 | Third escalation | GI settling for most | Appetite markedly reduced | Escalation |
| 12.5 mg | Weeks 17–20 | Fourth escalation | Nausea reducing | Body well-adapted | Escalation |
| 15 mg | Week 21+ | Maintenance | Side effects settle | Maximum licensed dose | Maintenance |
Important: The schedule above represents the standard clinical protocol. Your prescribing clinician or pharmacist may recommend a modified schedule — for example, spending six or eight weeks at each step — based on your individual tolerance and clinical response. Always follow the schedule agreed with your Happy Pharmacy prescribing team.
Dose by Dose
What to Expect at Each Dose Step
2.5 mg — The Starting Dose
Most patients tolerate the starting dose well. Mild nausea may occur around injection day but is rarely severe. Injection site reactions are common but transient. Weight loss at 2.5 mg is typically modest — 1 to 3 kg in the first four weeks. The primary goal at this stage is adaptation, not maximal efficacy. Many patients are surprised to notice meaningful appetite reduction and easing of food cravings even at this dose within the first week or two. Do not attempt to escalate early, even if the starting dose feels minimal — the four-week period is pharmacologically necessary, not a waiting room.
5 mg — First Escalation
Doubling from the starting dose, GLP-1 and GIP receptor stimulation increases meaningfully, producing more pronounced appetite suppression and gastric motility changes. Nausea is more commonly reported at 5 mg than at 2.5 mg, and diarrhoea is frequent in the first one to two weeks. Most patients find symptoms manageable within two weeks of the dose increase. Weight loss accelerates — patients begin to notice reduced portion sizes, decreased interest in snacking and more consistent weekly weight reductions. Stay well hydrated, as diarrhoea at this step increases dehydration risk.
7.5 mg — Second Escalation
The dose at which many patients experience their highest side effect burden. Dual receptor agonism is approaching meaningful therapeutic levels before full adaptation. Constipation often emerges alongside any remaining diarrhoea as gastric emptying slows further. Fatigue may persist but typically begins to ease. Appetite suppression becomes clinically significant at 7.5 mg — many patients report eating substantially smaller portions and reduced interest in previously appealing foods. Persist through this step: clinical data consistently shows that patients who continue past 7.5 mg go on to achieve the best long-term outcomes. Side effects here are transient.
10 mg — Third Escalation
For patients who cannot tolerate 12.5 mg or 15 mg, this dose may become a maintenance option with prescriber agreement. For many patients, the 10 mg step is noticeably more comfortable than 7.5 mg — side effects are typically settling and the body is increasingly adapted to tirzepatide's dual mechanism. Significant weight loss acceleration is common at this dose as appetite suppression is near its maximum. Maintain adequate protein intake — aim for 1.2 g per kg of body weight daily to preserve lean muscle mass at this level of appetite suppression.
12.5 mg — Fourth Escalation
One step from the maximum licensed dose, and for patients who experience intolerable side effects at 15 mg, 12.5 mg may be an appropriate long-term maintenance dose. Most patients find this step significantly easier than the 7.5 mg or 10 mg steps — the body has had 16 weeks to adapt and the incremental step from 10 mg is proportionally smaller. Average weight loss at 12.5 mg over 72 weeks in SURMOUNT-1 was approximately 20.9% of body weight. Use this step to embed the dietary and exercise habits — particularly resistance training — that will sustain weight loss at maintenance.
15 mg — The Maintenance Dose
For most patients, side effects at 15 mg are substantially reduced compared to the escalation phase. The body has had 20 weeks to adapt to tirzepatide, and the absence of further dose changes allows a new physiological equilibrium to establish. SURMOUNT-1 data shows 22.5% average weight loss at 15 mg over 72 weeks — the highest weight loss efficacy of any dose in the Mounjaro schedule and among the highest of any licensed weight management treatment. Continue as long as treatment remains effective and clinically appropriate.
Maintenance
Maintenance Dose: Clinical Outcomes by Dose Level
While 15 mg is the maximum licensed dose and produces the highest average weight loss, clinical practice reflects a range of maintenance doses depending on individual patient tolerance and clinical response.
| Maintenance Dose | Avg Weight Loss (SURMOUNT-1, 72 wks) | Typical Patient Profile |
|---|---|---|
| 10 mg | ~19.5% | Patients who experience intolerable side effects at higher doses; good responders who achieve goal weight at this level |
| 12.5 mg | ~20.9% | Patients who find 15 mg causes persistent GI symptoms; near-maximum efficacy with better tolerability |
| 15 mg | ~22.5% | Standard maintenance target; recommended for all patients who can tolerate full escalation |
Not All Patients Reach 15 mg — and That Is Clinically Acceptable: SURMOUNT trial data demonstrates meaningful and clinically significant weight loss at all dose levels. A patient who achieves and maintains 19.5% weight loss at 10 mg has achieved an exceptional outcome. The goal is the highest tolerated dose that produces sustained benefit — not the maximum dose at the cost of quality of life.
How Long Should Maintenance Continue?
Mounjaro is licensed and clinically positioned as a long-term treatment for chronic weight management. NICE TA1026 supports continued use as long as the patient continues to benefit and the treatment remains clinically appropriate. Stopping Mounjaro — like stopping any GLP-1 receptor agonist — is associated with significant weight regain. The SURMOUNT-4 withdrawal trial demonstrated that patients who discontinued tirzepatide regained a substantial proportion of lost weight within 12 months of stopping. Any planned discontinuation should be discussed with your prescribing pharmacist.
Missed Doses
What Happens If You Miss a Mounjaro Dose?
Missing an occasional Mounjaro dose is not a clinical emergency, but it requires a clear response. Tirzepatide has a half-life of approximately five days — shorter than semaglutide's seven-day half-life — meaning blood concentrations fall more quickly between injections, and the effects of a missed dose may be felt more promptly.
Why Consistency Matters
Mounjaro's shorter half-life means that maintaining a consistent weekly injection schedule is particularly important for sustained appetite suppression and treatment efficacy. Multiple missed doses can produce a meaningful drop in tirzepatide blood levels, leading to a resurgence of hunger and potential weight regain. Patients who travel frequently or have irregular schedules should plan ahead — setting a weekly reminder and carrying spare pens when travelling is strongly advised.
| Scenario | What to Do |
|---|---|
| Missed dose — 4 days or fewer have passed | Take the missed dose as soon as you remember. Resume your usual weekly injection day going forward. |
| Missed dose — more than 4 days have passed | Skip the missed dose entirely. Take your next dose on your usual scheduled day. Do not double up. |
| Missed multiple doses (1–2 weeks) | Resume on your normal schedule. Expect a temporary return of side effects. Contact your Happy Pharmacy team for guidance. |
| Extended break (4+ weeks) | Do not restart at your previous dose. Contact your prescribing clinician — a dose reduction and re-escalation is likely required. |
| Missed dose during escalation phase | Follow the rules above. Do not advance to the next dose step after a missed dose — complete a full four weeks at your current dose first. |
Practical Tip: Set a recurring weekly reminder on your phone for your Mounjaro injection day. If travelling across time zones, maintain the injection day as per UK time or discuss with your Happy Pharmacy team what adjustment is appropriate for extended trips.
Lower Doses
Can You Stay on a Lower Dose of Mounjaro?
Some patients ask whether it is possible to remain at a lower dose — such as 10 mg or 12.5 mg — rather than completing escalation to 15 mg. This is a clinically valid question with a nuanced answer.
When a Lower Maintenance Dose Is Appropriate
Remaining at a dose below 15 mg is a reasonable clinical decision when side effects at higher doses are intolerable despite dietary management and a slower escalation approach. This decision should always be made with your prescribing clinician rather than unilaterally. Both 10 mg and 12.5 mg produce clinically meaningful weight loss — the incremental efficacy gain from reaching 15 mg may not justify the quality-of-life impact for some patients.
Slower Escalation as an Alternative
For most patients experiencing intolerable side effects, a slower escalation schedule — spending six or eight weeks at each dose step rather than four — is a better option than remaining at a sub-maximum dose permanently. This allows more time for receptor adaptation, which typically resolves tolerability issues without permanently sacrificing efficacy. Your Happy Pharmacy prescribing team can advise whether a modified schedule is appropriate for your circumstances.
| Dose Option | Considerations | Clinical View |
|---|---|---|
| Remain at 10 mg | Tolerable for most; lower efficacy than 12.5 mg or 15 mg | Acceptable interim option with prescriber agreement |
| Remain at 12.5 mg | Near-maximum efficacy with better tolerability for some patients | Reasonable maintenance dose for patients who cannot tolerate 15 mg |
| Slower escalation to 15 mg | 6–8 weeks per step instead of 4; extends timeline to maintenance | Preferred approach over staying on a sub-maximum dose permanently |
| 15 mg standard maintenance | Maximum licensed dose; best efficacy data in SURMOUNT trials | Recommended target for all eligible patients |
Key Questions
Key Questions Answered
What is the Mounjaro dose schedule?
Mounjaro treatment begins at 2.5 mg once weekly for four weeks, then increases every four weeks through 5 mg, 7.5 mg, 10 mg and 12.5 mg before reaching the maximum maintenance dose of 15 mg at approximately week 21. The total escalation period is 20 weeks under the standard schedule. Once at 15 mg, patients continue on this maintenance dose indefinitely as long as treatment remains appropriate. All doses are administered as a once-weekly subcutaneous injection using a pre-filled auto-injector pen.
When do you increase Mounjaro?
Mounjaro doses are increased every four weeks under the standard schedule. This interval is clinically necessary — it allows the body's GLP-1 and GIP receptors to adapt to each dose level before stimulation is increased further. Escalating earlier than recommended substantially raises the risk of severe gastrointestinal side effects. Some patients follow a slower schedule of six or eight weeks per step, particularly if tolerability has been a challenge. Never increase your Mounjaro dose without discussing it with your prescribing clinician first.
What happens if I miss a Mounjaro dose?
If four or fewer days have passed since your missed Mounjaro dose, take it as soon as you remember and then resume your usual weekly injection day. If more than four days have passed, skip the missed dose and take your next dose on your usual scheduled day. For extended breaks of four weeks or more, contact your Happy Pharmacy prescribing team before restarting, as a dose reduction and re-escalation may be required. Mounjaro's half-life of approximately five days means that missed doses affect blood concentration more quickly than with semaglutide-based treatments.
FAQs
Frequently Asked Questions: Mounjaro Dose Schedule
Mounjaro treatment begins at 2.5 mg once weekly for four weeks, then increases every four weeks through 5 mg, 7.5 mg, 10 mg and 12.5 mg before reaching the maximum maintenance dose of 15 mg at approximately week 21. All doses are administered as a once-weekly subcutaneous injection.
The starting dose of Mounjaro is 2.5 mg once weekly. This is a tolerability dose designed to introduce tirzepatide's dual GLP-1/GIP mechanism gradually, allowing the body to adapt before escalation begins. It is taken for the first four weeks of treatment.
Most patients notice a reduction in appetite and food cravings within the first two weeks of starting Mounjaro, even at the 2.5 mg starting dose. Meaningful weight loss typically begins in the first month and accelerates as the dose increases through the escalation schedule.
The maximum licensed dose of Mounjaro is 15 mg once weekly. This is also the standard maintenance dose target and produces the highest average weight loss — approximately 22.5% of body weight over 72 weeks in SURMOUNT-1. There is no higher dose approved within the current prescribing framework.
No. The four-week intervals between dose increases are clinically necessary for receptor adaptation. Escalating faster significantly raises the risk of severe nausea, vomiting and dehydration. If you feel the current dose is having minimal effect, continue as scheduled — the full therapeutic effect builds across the entire escalation period.
Yes — remaining at 10 mg or 12.5 mg is clinically acceptable when 15 mg causes intolerable side effects despite dietary management. Both doses produce clinically meaningful weight loss. However, a slower escalation schedule — spending six or eight weeks at each step — is usually preferable to permanently staying below the maximum dose, as it allows more time for receptor adaptation without sacrificing long-term efficacy.
If four or fewer days have passed since your missed dose, take it as soon as you remember and resume your usual weekly day. If more than four days have passed, skip the missed dose and take your next dose on your usual scheduled day. For extended breaks of four weeks or more, contact your Happy Pharmacy prescribing team before restarting, as a dose reduction and re-escalation may be required.
Mounjaro has a six-step escalation schedule over 20 weeks (2.5 mg to 15 mg), while Wegovy has a four-step schedule over 16 weeks (0.25 mg to 2.4 mg). Mounjaro takes longer to reach maintenance but produces higher average weight loss — approximately 22.5% at 15 mg versus approximately 15% at Wegovy 2.4 mg in their respective landmark trials.
Mounjaro is designed as a long-term treatment for chronic weight management. Stopping treatment is associated with significant weight regain — as demonstrated in the SURMOUNT-4 withdrawal trial. Treatment should continue as long as the patient benefits, tolerates the medication and meets the clinical criteria. Any planned discontinuation should be discussed with your prescribing pharmacist.
If you experience intolerable side effects at 15 mg, speak to your Happy Pharmacy prescribing team. Options include reducing back to 12.5 mg, attempting a slower re-escalation to 15 mg after further adaptation time, or remaining at 12.5 mg as a long-term maintenance dose. Stopping treatment entirely is usually not necessary.
Yes — the injection day can be changed provided at least four days separate consecutive doses. Choose a new day you can maintain consistently, and inform your Happy Pharmacy team if you have any questions about managing the transition.
Yes. Mounjaro pens must be stored between 2°C and 8°C — typically in the main body of a household refrigerator, not the freezer or door. Pens should not be frozen. Once removed from the refrigerator, a Mounjaro pen can be kept at room temperature (up to 30°C) for up to 30 days. Happy Pharmacy dispatches all Mounjaro orders in validated cold-chain packaging.
Do not use a pen that appears damaged, leaking, discoloured or has been frozen. Contact your Happy Pharmacy team and do not inject with a pen you are unsure about. Using a compromised pen carries risks including inaccurate dosing and infection.
Ready to Start Mounjaro Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Browse Mounjaro Doses →
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. | Tirzepatide once a week for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626. | MHRA. Mounjaro (tirzepatide) prescribing information. 2023. | NICE TA1026. Tirzepatide for managing overweight and obesity. 2024. | Eli Lilly. Mounjaro Summary of Product Characteristics. 2023. | GPhC. Standards for registered pharmacies. 2023. | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.